Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

Background Targeting the cell-surface receptor EphA2, which is highly expressed in some solid tumors, is a novel approach for cancer therapy. We aimed to evaluate the safety profile, maximum tolerated dose (MTD), pharmacokinetics, and antitumor activity of MEDI-547, an antibody drug conjugate compos...

Descripción completa

Detalles Bibliográficos
Autores principales: Annunziata, Christina M., Kohn, Elise C., LoRusso, Patricia, Houston, Nicole D., Coleman, Robert L., Buzoianu, Manuela, Robbie, Gabriel, Lechleider, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553417/
https://www.ncbi.nlm.nih.gov/pubmed/22370972
http://dx.doi.org/10.1007/s10637-012-9801-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553417/
https://www.ncbi.nlm.nih.gov/pubmed/22370972
http://dx.doi.org/10.1007/s10637-012-9801-2

Ejemplares similares